Announcements Trials
Browse Landscape

Phase

Phase 1 102Phase 2 75Phase 1/2 51Phase 3 6Phase NA 5Phase EARLY_PHASE1 3Phase 2/3 3

Status

Withdrawn 1Suspended 1Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1

Conditions

Uveal Melanoma 1Primary Malignant Peripheral Nerve Sheath Tumors 1Ototoxicity 1Neoplasms, Germ Cell and Embryonal 1Hepatoblastoma 1

Interventions

Magnetic Resonance Spectroscopy 61Cyclophosphamide 57pembrolizumab 39fludarabine 38Radiotherapy 30Nivolumab 30Biopsy 27Metformin 23Fluorodeoxyglucose F18 22Bevacizumab 22Specimen Handling 21Temozolomide 18Cisplatin 18Radiosurgery 17Carboplatin 16Fluorouracil 15Paclitaxel 14Dexamethasone 14Radiation 13Gemcitabine 13Etoposide 13Rituximab 12Positron Emission Tomography Computed Tomography 12Letrozole 12Irinotecan 12gallium 68 PSMA-11 11durvalumab 11atezolizumab 11X-Rays 11Surgical Procedures, Operative 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Vorinostat × Clear all
NCT06693284 2026-02-03

A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]

University of Minnesota

Phase EARLY_PHASE1 Recruiting
8 enrolled

Primary Malignant Peripheral Nerve Sheath Tumors

NCT05756660 2025-10-20

Sodium Thiosulfate Otoprotection During Salvage Cisplatin Therapy

Children's Hospital Medical Center, Cincinnati

Phase EARLY_PHASE1 Suspended
33 enrolled
Gastrointestinal

Ototoxicity, Neoplasms, Germ Cell and Embryonal, Hepatoblastoma

NCT03022565 2020-02-06

Vorinostat in Patients With Class 2 High Risk Uveal Melanoma

University of Miami

Phase EARLY_PHASE1 Withdrawn
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡